• Something wrong with this record ?

Thiopurine-induced toxicity is associated with dysfunction variant of the human molybdenum cofactor sulfurase gene (xanthinuria type II)

B. Stiburkova, K. Pavelcova, L. Petru, J. Krijt,

. 2018 ; 353 (-) : 102-108. [pub] 20180620

Language English Country United States

Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: The aim of our study was to identify the genetic background of thiopurine-induced toxicity in a patient with a wild-type thiopurine methyltransferase genotype and activity. A 38-year-old Caucasian woman presented with cutaneous necrotizing vasculitis pancytopenia one month after starting azathioprine therapy. METHODS: During a routine biochemical follow-up of the patient, undetectable serum uric acid (<10 μl) was observed. A high performance liquid chromatography analysis of urinary purines revealed increased levels of xanthine (137 mmol/mol creatinine). The suspected diagnosis of hereditary xanthinuria, a rare autosomal recessive disorder of the last two steps of purine metabolism, was confirmed by sequence analysis. RESULTS: An analysis of XDH/XO and AOX1 revealed common polymorphisms, while analysis of the MOCOS gene identified a rare homozygous variant c.362C > T. Dysfunction of this variant was confirmed by significantly decreased xanthine dehydrogenase/oxidase activity in the patient's plasma (<2% of control mean activity). CONCLUSIONS: We present a biochemical, enzymatic, and molecular genetic case study suggesting an important association between a hitherto undescribed dysfunction variant in the MOCOS gene and thiopurine-induced toxicity. The identified variant c.362C > T results in slower thiopurine metabolism caused by inhibition of 6-mercaptopurine oxidation (catabolism) to 6-thioxanthine and 6-thiouric acid, which increases the formation of the nucleotide 6-thioguanine, which is toxic. This is the first clinical case to identify the crucial role of the MOCOS gene in thiopurine intolerance and confirm the impact of genetic variability of purine enzymes on different therapeutic outcomes in patients undergoing thiopurine treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028355
003      
CZ-PrNML
005      
20190816124350.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.taap.2018.06.015 $2 doi
035    __
$a (PubMed)29935280
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Stiburkova, Blanka $u Institute of Rheumatology, Prague, Czech Republic; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic. Electronic address: stiburkova@revma.cz.
245    10
$a Thiopurine-induced toxicity is associated with dysfunction variant of the human molybdenum cofactor sulfurase gene (xanthinuria type II) / $c B. Stiburkova, K. Pavelcova, L. Petru, J. Krijt,
520    9_
$a BACKGROUND: The aim of our study was to identify the genetic background of thiopurine-induced toxicity in a patient with a wild-type thiopurine methyltransferase genotype and activity. A 38-year-old Caucasian woman presented with cutaneous necrotizing vasculitis pancytopenia one month after starting azathioprine therapy. METHODS: During a routine biochemical follow-up of the patient, undetectable serum uric acid (<10 μl) was observed. A high performance liquid chromatography analysis of urinary purines revealed increased levels of xanthine (137 mmol/mol creatinine). The suspected diagnosis of hereditary xanthinuria, a rare autosomal recessive disorder of the last two steps of purine metabolism, was confirmed by sequence analysis. RESULTS: An analysis of XDH/XO and AOX1 revealed common polymorphisms, while analysis of the MOCOS gene identified a rare homozygous variant c.362C > T. Dysfunction of this variant was confirmed by significantly decreased xanthine dehydrogenase/oxidase activity in the patient's plasma (<2% of control mean activity). CONCLUSIONS: We present a biochemical, enzymatic, and molecular genetic case study suggesting an important association between a hitherto undescribed dysfunction variant in the MOCOS gene and thiopurine-induced toxicity. The identified variant c.362C > T results in slower thiopurine metabolism caused by inhibition of 6-mercaptopurine oxidation (catabolism) to 6-thioxanthine and 6-thiouric acid, which increases the formation of the nucleotide 6-thioguanine, which is toxic. This is the first clinical case to identify the crucial role of the MOCOS gene in thiopurine intolerance and confirm the impact of genetic variability of purine enzymes on different therapeutic outcomes in patients undergoing thiopurine treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a aldehydoxidasa $x nedostatek $x genetika $7 D042931
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a merkaptopurin $x škodlivé účinky $x analogy a deriváty $x metabolismus $7 D015122
650    _2
$a methyltransferasy $x genetika $7 D008780
650    _2
$a polymorfismus genetický $x genetika $7 D011110
650    _2
$a poruchy metabolismu purinů a pyrimidinů $x genetika $7 D011686
650    _2
$a sulfurtransferasy $x genetika $7 D013466
650    _2
$a kyselina močová $x krev $7 D014527
650    _2
$a xanthin $x moč $7 D019820
650    _2
$a xanthindehydrogenasa $x nedostatek $x genetika $7 D014968
650    _2
$a xanthinoxidasa $x genetika $7 D014969
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavelcova, Katerina $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Petru, Lenka $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Krijt, Jakub $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic.
773    0_
$w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 353, č. - (2018), s. 102-108
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29935280 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190816124620 $b ABA008
999    __
$a ok $b bmc $g 1433504 $s 1066815
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 353 $c - $d 102-108 $e 20180620 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...